Scholarlink

Background <p><i>Helicobacter pylori</i> (Hp) is a globally prevalent gastrointestinal pathogen and a major etiological agent in various digestive tract disorders. Ultra violet C (UVC) light represents a promising physical modality for the treatment of Hp infection, owing to its capacity for non-invasive endoscopic delivery to eradicate the bacterium within the gastric environment.</p> Objective <p>The purpose of this study was to investigate the efficacy and safety of UVC-LED (254/265/275 nm) in the treatment of Hp, both in <i>vitro</i> and in <i>vivo</i>.</p> Methods <p>The bactericidal effect of UVC-LED irradiation against <i>H. pylori</i> was assessed in vitro and in an animal infection model. Gastric tissue damage and therapeutic efficacy were evaluated via H&amp;E, γ-H2AX, TUNEL staining and digestive function of the stomach.</p> Results <p>UVC-LEDs emitting at 254, 265, and 275&#xa0;nm exhibited significant anti-<i>H. pylori</i> activity. However, a clear divergence in safety profiles was observed. The 275&#xa0;nm wavelength achieved substantial bacterial load reduction while inducing minimal DNA damage and cellular apoptosis, as evidenced by significantly lower levels of γ-H2AX and TUNEL positivity compared to the 254&#xa0;nm and 265&#xa0;nm group at the critical 1-day and 3-day timepoints (<i>p</i> &lt; 0.05). Histological analysis confirmed that this attenuated cellular damage correlated with preserved mucosal architecture in the 275&#xa0;nm treatment group. Furthermore, none of the three wavelengths showed any significant adverse impact on gastric digestive function.</p> Conclusions <p>The 275&#xa0;nm UVC-LED emerges as an effective and tissue-compatible physical therapy for <i>H. pylori</i> infection, combining robust bactericidal activity with enhanced mucosal safety. This modality shows promise as a novel complementary approach to conventional antibiotic-based regimens.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of ultraviolet C therapy for the eradication of Helicobacter pylori

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月10日

查看全文
  • Ming’e Wu,
  • Yan Li,
  • Guxiang Zhou,
  • Zhenyu Li,
  • Rongxin He,
  • Qingqing Yang,
  • Mengyun Ke,
  • Nana Zhang,
  • Xiaoyan Zeng,
  • Yi Lyu

摘要

Background

Helicobacter pylori (Hp) is a globally prevalent gastrointestinal pathogen and a major etiological agent in various digestive tract disorders. Ultra violet C (UVC) light represents a promising physical modality for the treatment of Hp infection, owing to its capacity for non-invasive endoscopic delivery to eradicate the bacterium within the gastric environment.

Objective

The purpose of this study was to investigate the efficacy and safety of UVC-LED (254/265/275 nm) in the treatment of Hp, both in vitro and in vivo.

Methods

The bactericidal effect of UVC-LED irradiation against H. pylori was assessed in vitro and in an animal infection model. Gastric tissue damage and therapeutic efficacy were evaluated via H&E, γ-H2AX, TUNEL staining and digestive function of the stomach.

Results

UVC-LEDs emitting at 254, 265, and 275 nm exhibited significant anti-H. pylori activity. However, a clear divergence in safety profiles was observed. The 275 nm wavelength achieved substantial bacterial load reduction while inducing minimal DNA damage and cellular apoptosis, as evidenced by significantly lower levels of γ-H2AX and TUNEL positivity compared to the 254 nm and 265 nm group at the critical 1-day and 3-day timepoints (p < 0.05). Histological analysis confirmed that this attenuated cellular damage correlated with preserved mucosal architecture in the 275 nm treatment group. Furthermore, none of the three wavelengths showed any significant adverse impact on gastric digestive function.

Conclusions

The 275 nm UVC-LED emerges as an effective and tissue-compatible physical therapy for H. pylori infection, combining robust bactericidal activity with enhanced mucosal safety. This modality shows promise as a novel complementary approach to conventional antibiotic-based regimens.

Graphical Abstract